Skip to content

Preliminary results from a Phase 1b trial of oral synthetic retinoid for the treatment of RP due to mutations in RPE65 and LRAT genes

QLT Inc., (NASDAQ: QLTI) a Canadian based biotechnology company headquartered in Vancouver, has announced that its oral synthetic retinoid product, QLT091001, has shown positive preliminary results in a study of 17 RP patients. The oral synthetic retinoid is a synthetic retinoid replacement for 11-cis-retinal which plays a key role in visual biochemistry and is designed for the treatment of retinal diseases caused by gene mutations that interfere with the availability of 11-cis retinal. The company announced that the results of the Phase 1b study showed “rapid, statistically significant and clinically meaningful changes in visual fields from baseline values”.